Amgen Inc

AMGNNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

540.6M

on 2026-06-30, from 536.4M on 2024-03-31 10-Q ↗

Newest

No limit

S-3ASR of 2026-02-13. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗

None

No at-the-market programme on file in the last 30 months.

Warrants

The 10-Q filed 2026-08-05 is not read yet.

Cash

$13.99B

Operating cash flow was positive over the four quarters to 2026-06-30, so no quarters are counted. 10-Q ↗

Raised: 1 of its filings are not read yet.